as part of the relaunch france plan
Press release
Advanced BioDesign and the Inserm TAGC laboratory will receive a total of €208,000 to support the development of their CRISPALDHin project over the next two years. CRISPALDHin project aims at developing adaptive and personalised treatments targeting multiple genomic alterations involving aldehyde dehydrogenases 1 (ALDH 1) which are at the root of cancers resistance.